Effectiveness and Safety of Tenecteplase in Clinical Uses for Patients with ST-Elevation Myocardial Infarction, Damnoen Saduak Hospital, Ratchaburi Province
Keywords:
Fibrinolytic agents, Acute coronary syndrome, Chest painAbstract
The purpose of this retrospective descriptive research was to determine effectiveness and safety of Tenecteplase in clinical uses for patients with ST-Elevation Myocardial Infarction at Damnoen Saduak hospital. The data were collected through electronic database and medical records of patients with STEMI who received Tenecteplase from January 1, 2019, to July 31, 2022 at Damnoen Saduak hospital. The study results revealed as follows:
1. As for effectiveness aspect, there were 16 STEMI patients (39.02%) had ST-segment reduction of at least 50% and 29 of 41 patients (70.63%) recovered from chest pain.
2. As for safety aspect, there were 9 patients (21.95%) had adverse reactions. There were only 3 cases of hemorrhage (7.32%), 1 case of major bleeding and 3 cases of hypotension (7.32%). There was no report of hypersensitivity reactions.
According to the study results, Tenecteplase was effective in relieving chest pain and safety due to low bleeding complications. Therefore, Tenecteplase should be recommended for first-line fibrinolytic agents in patients with STEMI.
References
Aylward, P. E. (2001). Efficacy and safety of Tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. The Lancet, 358(9282), 605–613. https://doi.org/10.1016/s0140-6736(01)05775-0
Duangmee, K., Boonmuang, P., Santimaleeworagun, W., & Prasitdumrong, H. (2022). Urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents. Asian Pacific Journal of Allergy and Immunology, 40(4), 379-385. https://doi.org/10.12932/ap-050619-0574
Dunn, C. J., & Goa, K. L. (2001). Tenecteplase . American Journal of Cardiovascular Drugs, 1(1), 51–66. https://doi.org/10.2165/00129784-200101010-00006
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology, 5(1). https://doi.org/10.1186/1471-2288-5-13
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., . . . Widimský, P. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 39(2), 119–177. https://doi.org/10.1093/eurheartj/ehx393
Likittanasombat, K., Buddhari, W., Kositchaiwat, J., Kunjara, Na Ayudhya, R., Srimahachota, S., Tungsubutra, W. (2020). Thai Acute Coronary Syndrome Guidelines 2020. Samut Prakan: Nextstep D-sign. (in Thai)
National Drug Information. (2022). National list of essential medicines. http://ndi.fda.moph.go.th/drug_national
Prasitdumrong, H., Duangmee, K., Boonmuang, P., Santimaleeworagun, W., Oppamayun, Y., Sonsupap, C., & Nakkaratniyom, T. (2023). Incidence of urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents in Thailand using the database of the health product vigilance center. Asian Pacific Journal of Allergy and Immunology, 41(1), 67-75. https://doi.org/10.12932/ap-181119-0694
Srisubat, A., Saejueng, B., Romtan, P., Tangwerapornpong, S., Hengrussamee, K., & Potisat, S. (2014). Cost-effectiveness analysis of Tenecteplase (TNK) compared with Streptokinase (SK) in treating ST-Elevated Myocardial Infarction (STEMI). Journal of the Department of Medical Services, 39(3), 173-183. (in Thai)
Strategy and Planning Division. (2021). Public health statistics A.D. 2021. Nonthaburi: Ministry of Public Health. (in Thai)
Thai ACS Registry. (2022). Summary of Thai ACS Registry 2022. http://www.ncvdt.org/Default.aspx
Van De Werf, F. (1999). Single-bolus Tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. The Lancet, 354(9180), 716–722. https://doi.org/10.1016/s0140-6736(99)07403-6
Van De Werf, F., Cannon, C. P., Luyten, A., Houbracken, K., McCabe, C. H., Berioli, S., Bluhmki, E., Sarelin, H., Wang-Clow, F., Fox, N. E., & Braunwald, E. (1999). Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. American Heart Journal, 137(5), 786–791. https://doi.org/10.1016/s0002-8703(99)70400-x
Van De Werf, F., Ross, A., Armstrong, P. W., & Granger, C. B. (2006). Primary versus Tenecteplase -facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. The Lancet, 367(9510), 569–578. https://doi.org/10.1016/s0140-6736(06)68147-6
Downloads
Published
Issue
Section
License
Copyright (c) 2023 ฺ
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารนี้ถือว่าเป็นลิขสิทธิ์ของวิทยาลัยพยาบาลบรมราชชนนี ราชบุรี และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
